DIAGNOS Welcomes Mr. Francis Bellido to its Board of Directors
November 28 2019 - 2:00PM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce the appointment,
effective November 27, 2019, of Mr. Francis Bellido to the
Corporation’s board of directors (the “Board”).
Mr. Bellido has spent his career overseeing and
leading the development of several organizations in the healthcare
industry. He brings sound financial management expertise, deep
operating and leadership experience, and a global business
perspective that he acquired over 30 years of international
experience in the Biosciences, Healthcare and Financial industries.
Notably, Mr. Bellido managed a CA$300M life science investment Fund
(SGF-Santé) that produced several key players in the Medical Device
industry.
“We are pleased that Francis has accepted to
join the Board. His great knowledge of the healthcare industry and
his business relationships will directly contribute to the growth
of our business,” said Mr. François Côté, Chairman of the
Board.
The Corporation also announces that it has
received acceptance from the TSX Venture for the issuance of
3,076,922 non-transferable share purchase warrants as part of a
short term financing of CA$400,000 detailed in the November 26,
2019 press release on the same subject.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS IncTel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024